Skip to main content

FY2022 Consolidated Financial Overview

[Based on Japanese GAAP]

Operating Results

Operating Results Summary

  • Net sales

    60,461 million yen

    YOY 6.8%

  • Operating profit

    5,108 million yen

    YOY 6.5%

  • Ordinary profit

    5,232 million yen

    YOY 7.2%

  • Profit attributable to owners of parent

    4,238 million yen

    YOY (1.2%)

  • Earnings per share

    150.08 yen

    YOY (0.75%)

The Group’s net sales in the consolidated fiscal year under review were 60,461 million yen, up 3,853 million yen year on year (YoY). This was due mainly to increased sales in the Animal Health Business, which experienced favorable sales of feed additives, in addition to growth in the Medical Pharmaceuticals Business driven by the introduction of new products and other factors. Cost of sales was 31,876 million yen, down 0.7% YoY, resulting in an increase of 2,233 million yen in gross profit to 28,584 million yen. At the same time, selling, general and administrative expenses rose by 1,920 million yen YoY to 23,476 million yen, and as a result operating profit was up 312 million yen YoY to 5,108 million yen, for a ratio of operating profit to net sales of 8.4%. Ordinary profit was 5,232 million yen, after recording 433 million yen in non-operating income and 308 million yen in non-operating expenses. While we recorded 124 million yen during the period in extraordinary income associated with sale of investment securities, due to factors including a rebound from the recording of extraordinary income associated with sale of property, plant, and equipment in the same period last year, profit for the period attributable to owners of parent was down 51 million yen to 4,238 million yen.

Segment

Net sales

(Millions of yen)

Segment name 1Q 2Q 3Q Full year
Pharmaceutical business 13,646 26,851 41,916 53,579
Animal Health business 1,593 3,234 5,187 6,660
Other businesses 29 86 155 220

(i) Pharmaceutical business

The pharmaceutical drug business, which focuses on the three fields of internal medicine, obstetrics and gynecology, and urology, showed favorable trends overall, despite the impact of the periodical NHI drug price revisions. A look at results by product shows that results in the obstetrics and gynecology area were driven by the large-scale growth in the uterine fibroid and endometriosis agent RELUMINA (relugolix), to 8,839 million yen (up 20.5% YoY), and steady growth in the dysmenorrhea agent FREWELL (norethisterone/ ethinylestradiol), to 3,489 million yen (up 0.8% YoY), despite more than approximately 10% reduction in the NHI price revision in April 2022. In addition to these, the dysmenorrhea agent DroEthi (drospirenone/ ethinylestradiol), which went on sale in June 2022, largely drove performance with sales of 3,671 million yen. Furthermore, both the major products of internal medicine, the thyroid hormone agent THYRADIN and the poorly absorbable rifamycin antimicrobial agent RIFXIMA, for which we carried out activities intended to achieve its solid incorporation into clinical practice guidelines, showed steady growth, of 7,733 million yen (up 3.1% YoY) and 5,397 million yen (up 11.2% YoY), respectively. In the urology field, sales of the LH-RH derivative microcapsule sustained release agent LEUPRORELIN were 4,999 million yen (down 3.6% YoY).

As a result of the above factors, net sales were 53,579 million yen (up 5.5% YoY) in this segment, and segment profit was 5,779 million yen (up 13.6% YoY).

(ii) Animal health business

Sales of the animal health business, which sells products such as veterinary pharmaceuticals and feed additives, grew to 6,660 million yen (up 18.3% YoY), thanks to strong sales of feed additives products. Segment profit was 409 million yen (up 8.6% YoY).

(iii) Other businesses

Sales results for other businesses, which include clinical testing, medical devices, and supplements, grew to 220 million yen (up 19.0% YoY). The hair-growth hormone measurement kits that launched in the previous fiscal year made a positive contribution to sales. However, Segment loss was 6 million yen (vs. a loss of 16 million yen in the same period of the previous year).

Financial Position

Financial Position Summary

  • Total assets

    87,138 million yen

    Change from end of previous fiscal year 4.6%

  • Net assets

    54,533 million yen

    Change from end of previous fiscal year 11.5%

  • Equity ratio

    62.6 %

    Change from end of previous fiscal year 3.9point

Overview of Financial Position

(Assets)

Total assets at the end of the consolidated fiscal year under review stood at 87,138 million yen, up 3,840 million yen from the end of the previous consolidated fiscal year. This figure was due primarily to increases in accounts such as cash and deposits, notes and accounts receivable - trade, and contract assets, raw materials and supplies, and investment securities, and others, despite decreases in distributorship and securities.

(Liabilities)

Total liabilities at the end of the consolidated fiscal year under review stood at 32,604 million yen, down 1,800 million yen from the end of the previous consolidated fiscal year. This figure was due primarily to decreases in long-term borrowings including current portion, and electronically recorded obligations - operating.

(Net assets)

Total assets at the end of the consolidated fiscal year under review stood at 54,533 million yen, up 5,641 million yen from the end of the consolidated fiscal previous year. This figure was due primarily to an increase in retained earnings resulting from the recording of profit attributable to owners of parent and an increase in valuation difference on available-for-sale securities reflecting rising share prices.

The resulting equity ratio was 62.6%, up 3.9 percentage points from the end of the previous consolidated fiscal year.

Cash Flow Summary

  • Cash flows from operating activities

    3,351 million yen

  • Cash flows from investing activities

    (1,126) million yen

  • Cash flows from financing activities

    (1,820) million yen

  • Cash and cash equivalents at end of period

    17,505 million yen

Overview of Cash Flow Position

The balance of cash and cash equivalents at the end of the current consolidated fiscal year stood at 17,505 million yen, up 402 million yen from the end of the previous consolidated fiscal year.

(Cash flows from operating activities)

Net cash provided by operating activities was 3,351 million yen (vs. a gain of 2,842 million yen in the same period of the previous year), due mainly to profit before income taxes, impairment, and depreciation, which more than offset proceeds from sale of property, plant and equipment.

(Cash flows from investing activities)

Net cash used by investing activities was 1,126 million yen (vs. a gain of 6,743 million yen in the same period of the previous year). This was due mainly to acquisition of property, plant, and equipment and of securities.

(Cash flows from financing activities)

Net cash used in financing activities was 1,820 million yen (vs. a loss of 2,996 million yen in the same period of the previous year). This was due mainly to repayments of long-term borrowings.